PhytoMedical in new diabetes drug investigation

The field of diabetes treatment is by no means frozen in stasis. New technology is expanding treatment horizons rapidly, whether through inhaled insulin systems, stem cell research or drug treatment. News today is that PhytoMedical Technologies has revealed novel research into diabetes drug compounds.
The company claims that these specific compounds, known as ‘polyphenolic’, are distinct from any other class of diabetes drugs. They were developed by the company, and act to improve insulin functioning and lower blood sugar levels. Furthermore, and most interestingly, the drugs have also been shown to act as antioxidants. They are reported to guard the body from free radical damage, preserving healthy cells and staving off complications.
The compounds also improve bodily sensitivity to insulin, and essential part of diabetes treatment. The compounds are derived from cinnamon and their effect on the body is remarkable. They reduce blood sugar levels, triglycerides, LDL and total cholesterol. There are apparently no side effects from the drugs, and as such they fall outside the five different classifications of diabetes pills in the USA.
The potential of polyphenol compounds in changing the way we look at diabetes treatment is enormous.